Several other equities analysts also recently commented on the company. Chardan Capital restated a “buy” rating and issued a $72.50 price objective on shares of Crispr Therapeutics in a research report on Thursday, February 13th. Oppenheimer boosted their target price on Crispr Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday, November 25th. Roth Capital boosted their target price on Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. William Blair reiterated a “buy” rating on shares of Crispr Therapeutics in a research report on Thursday, February 13th. Finally, Goldman Sachs Group boosted their target price on Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 19th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and thirteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $78.29.
Shares of Crispr Therapeutics stock opened at $56.76 on Friday. The stock’s 50-day simple moving average is $56.75 and its 200-day simple moving average is $53.19. Crispr Therapeutics has a 52 week low of $30.75 and a 52 week high of $74.00. The company has a market capitalization of $3.39 billion, a price-to-earnings ratio of 58.52 and a beta of 3.25.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.51 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $1.19. Crispr Therapeutics had a return on equity of 11.74% and a net margin of 23.09%. The business had revenue of $77.00 million for the quarter, compared to the consensus estimate of $39.08 million. During the same period in the previous year, the business earned ($0.92) earnings per share. The business’s revenue was up 76900.0% on a year-over-year basis. Analysts forecast that Crispr Therapeutics will post -4.48 earnings per share for the current year.
Large investors have recently bought and sold shares of the stock. NEXT Financial Group Inc lifted its position in shares of Crispr Therapeutics by 915.0% in the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after buying an additional 549 shares in the last quarter. Coastal Investment Advisors Inc. purchased a new stake in shares of Crispr Therapeutics in the third quarter worth about $26,000. Farmers & Merchants Trust Co of Chambersburg PA purchased a new stake in shares of Crispr Therapeutics in the fourth quarter worth about $26,000. Webster Bank N. A. bought a new stake in Crispr Therapeutics during the fourth quarter worth approximately $26,000. Finally, Advisory Services Network LLC increased its stake in Crispr Therapeutics by 146.0% during the fourth quarter. Advisory Services Network LLC now owns 674 shares of the company’s stock worth $41,000 after acquiring an additional 400 shares during the last quarter. Institutional investors own 51.28% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: What is the Beige Book?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.